Skip to main content

Sonoma Pharmaceuticals, Inc. (SNOA) Stock Forecast 2025 - AI Price Prediction & Analysis


Sonoma Pharmaceuticals, Inc. (SNOA) AI Stock Price Forecast & Investment Analysis

Sonoma Pharmaceuticals, Inc. Stock Price Chart and Technical Analysis

Loading Sonoma Pharmaceuticals, Inc. interactive price chart and technical analysis...

Sonoma Pharmaceuticals, Inc. (SNOA) - Comprehensive Stock Analysis & Investment Research

Deep dive into Sonoma Pharmaceuticals, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Sonoma Pharmaceuticals, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals, Inc. operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

Sonoma Pharmaceuticals, Inc. (Stock Symbol: SNOA) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 26 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Sonoma Pharmaceuticals, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Sonoma Pharmaceuticals, Inc.: With $14M in annual revenue and -74.0% net margin, the company demonstrates developing profitability.

Annual Revenue: $14 million generating a -74.0% net profit margin .

Market Capitalization: $7 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -49.4% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Sonoma Pharmaceuticals, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For Sonoma Pharmaceuticals, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Sonoma Pharmaceuticals, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Sonoma Pharmaceuticals, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Sonoma Pharmaceuticals, Inc.: Market positioning analysis based on available financial and operational metrics.

Sonoma Pharmaceuticals, Inc. strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 66.3% gross margin, indicating strong pricing power and operational efficiency.

Sonoma Pharmaceuticals, Inc. (SNOA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Sonoma Pharmaceuticals, Inc. stock analysis.

Loading Sonoma Pharmaceuticals, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Sonoma Pharmaceuticals, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Sonoma Pharmaceuticals, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Sonoma Pharmaceuticals, Inc.: With a P/E ratio of -5.63, the market sees the stock as potentially undervalued.

P/E Ratio -5.63x
P/B Ratio 1.69x
Market Cap $7M
EPS $-3.48
Book Value/Share $2.47
Revenue/Share $9.08
FCF/Share $-3.02
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Sonoma Pharmaceuticals, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Sonoma Pharmaceuticals, Inc.: An ROE of -49.4% indicates room for improvement in shareholder value creation.

ROE -49.4%
ROA -30.9%
ROIC -43.5%
Gross Margin 66.3%
Operating Margin -68.6%
Net Margin -74.0%
EBT Margin -38.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Sonoma Pharmaceuticals, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Sonoma Pharmaceuticals, Inc.: A current ratio of 4.57 indicates strong liquidity.

Current Ratio 4.57x
Quick Ratio 2.94x
D/E Ratio 0.03x
Financial Leverage 1.73x
Interest Coverage -324.2x
Working Capital $9M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Sonoma Pharmaceuticals, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Sonoma Pharmaceuticals, Inc.: Free cash flow of $-4M indicates cash challenges that need attention.

Operating Cash Flow $-4M
Free Cash Flow $-4M
FCF/Sales -35.3%
CapEx/Sales 0.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Sonoma Pharmaceuticals, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Sonoma Pharmaceuticals, Inc.: An asset turnover of 0.66x suggests room for improvement in asset utilization.

Asset Turnover 0.66x
Receivables Turnover 3.4x
Inventory Turnover 3.0x
Fixed Assets Turnover 12.5x
Days Sales Outstanding 106 days
Days Inventory 121 days
Payables Period 83 days
Cash Conversion Cycle 144 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Sonoma Pharmaceuticals, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Sonoma Pharmaceuticals, Inc.: With annual revenue of $14M, Sonoma Pharmaceuticals, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $14M
Operating Income $-8M
Net Income $-8M
R&D Expense $2M
SG&A Expense $73M
Cost of Goods Sold $4M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 91%
Cash & Short-term Investments 44%
Total Liabilities 42%
Short-term Debt 3%
Accounts Receivable 15%
Inventory 15%
Dividend & Shareholder Information
Shares Outstanding 2M
Growth Metrics (YoY)
EPS Growth -36.1%

Latest Sonoma Pharmaceuticals, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Sonoma Pharmaceuticals, Inc. (SNOA) stock price and investment outlook.

Sonoma Pharmaceuticals, Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Sonoma Pharmaceuticals, Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $26M x 3.0x
ALUR Unlock Forecast - 30 Days FREE Trial $17M -0.4x -0.3x
ANGO Unlock Forecast - 30 Days FREE Trial $442M -1.4x 2.4x
ANIK Unlock Forecast - 30 Days FREE Trial $128M -4.3x 0.9x
AORT Unlock Forecast - 30 Days FREE Trial $1805M -198.2x 4.3x
APYX Unlock Forecast - 30 Days FREE Trial $89M -3.5x 12.3x
ATEC Unlock Forecast - 30 Days FREE Trial $2274M -7.4x 95.7x
ATRC Unlock Forecast - 30 Days FREE Trial $1810M -39.6x 3.9x
AVHHL Unlock Forecast - 30 Days FREE Trial $27M x x
BAX Unlock Forecast - 30 Days FREE Trial $12132M -94.9x 1.7x
BBNX Unlock Forecast - 30 Days FREE Trial $976M x 3.2x
BDX Unlock Forecast - 30 Days FREE Trial $53749M 33.9x 2.1x
BEAT Unlock Forecast - 30 Days FREE Trial $57M -5.7x 13.8x
BJDX Unlock Forecast - 30 Days FREE Trial $2M -0.5x 0.4x
BSX Unlock Forecast - 30 Days FREE Trial $144402M 57.6x 6.4x
BVS Unlock Forecast - 30 Days FREE Trial $595M -18.3x 3.7x
CARL Unlock Forecast - 30 Days FREE Trial $-20M x x
CLPT Unlock Forecast - 30 Days FREE Trial $318M -23.5x 16.1x
CODX Unlock Forecast - 30 Days FREE Trial $16M -0.7x 0.4x
CVRX Unlock Forecast - 30 Days FREE Trial $187M -5.5x 3.2x
DCTH Unlock Forecast - 30 Days FREE Trial $460M 206.2x 4.4x
DRTS Unlock Forecast - 30 Days FREE Trial $348M x 4.0x
DXCM Unlock Forecast - 30 Days FREE Trial $28299M 49.5x 11.0x
EBRCZ Unlock Forecast - 30 Days FREE Trial $337M x 6.8x
FEMY Unlock Forecast - 30 Days FREE Trial $11M -1.4x 7.6x
FOFA Unlock Forecast - 30 Days FREE Trial $8M x 14.6x
GIPL Unlock Forecast - 30 Days FREE Trial $5M x 25.6x
GKOS Unlock Forecast - 30 Days FREE Trial $4914M -46.3x 6.4x
GMED Unlock Forecast - 30 Days FREE Trial $7839M 22.0x 1.8x
HRGN Unlock Forecast - 30 Days FREE Trial $31M x 40.6x
IART Unlock Forecast - 30 Days FREE Trial $1099M 200.2x 1.1x
ICCM Unlock Forecast - 30 Days FREE Trial $62M x 21.3x
ICUI Unlock Forecast - 30 Days FREE Trial $3248M -49.8x 1.6x
IDXG Unlock Forecast - 30 Days FREE Trial $23M 4.4x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $30M x 7.0x
IINNW Unlock Forecast - 30 Days FREE Trial $8M x 1.9x
INBS Unlock Forecast - 30 Days FREE Trial $9M -0.3x 3.0x
INFU Unlock Forecast - 30 Days FREE Trial $213M 42.0x 3.9x
INSP Unlock Forecast - 30 Days FREE Trial $2365M 44.5x 3.5x
IRMD Unlock Forecast - 30 Days FREE Trial $905M 43.8x 9.6x
IRTC Unlock Forecast - 30 Days FREE Trial $5663M -20.2x 54.6x
KIDS Unlock Forecast - 30 Days FREE Trial $448M -20.7x 1.3x
KMTS Unlock Forecast - 30 Days FREE Trial $1350M x x
KRMD Unlock Forecast - 30 Days FREE Trial $192M -19.8x 11.6x
LNSR Unlock Forecast - 30 Days FREE Trial $59M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $111M -0.6x 14.1x
LUNG Unlock Forecast - 30 Days FREE Trial $69M -4.3x 1.0x
MCAG Unlock Forecast - 30 Days FREE Trial $22M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $21M x -9.9x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.8x 13.4x
MDXG Unlock Forecast - 30 Days FREE Trial $1050M 32.6x 4.9x
MGRM Unlock Forecast - 30 Days FREE Trial $211M -10.7x 24.5x
MHUA Unlock Forecast - 30 Days FREE Trial $13M x 0.1x
MMM Unlock Forecast - 30 Days FREE Trial $85312M 21.7x 19.9x
MMSI Unlock Forecast - 30 Days FREE Trial $5093M 42.8x 3.4x
NEPH Unlock Forecast - 30 Days FREE Trial $39M -20.3x 2.0x
NMTC Unlock Forecast - 30 Days FREE Trial $46M -1.7x 5.7x
NPCE Unlock Forecast - 30 Days FREE Trial $328M -10.4x 16.9x
NSPR Unlock Forecast - 30 Days FREE Trial $124M -4.3x 6.1x
NVCR Unlock Forecast - 30 Days FREE Trial $1419M -20.8x 4.1x
NXGL Unlock Forecast - 30 Days FREE Trial $22M -6.8x 4.6x
OBIO Unlock Forecast - 30 Days FREE Trial $118M -3.4x 2.0x
OFIX Unlock Forecast - 30 Days FREE Trial $581M -5.8x 1.3x
OSRH Unlock Forecast - 30 Days FREE Trial $25M x 0.3x
OSUR Unlock Forecast - 30 Days FREE Trial $253M 17.1x 0.7x
PAVM Unlock Forecast - 30 Days FREE Trial $20M 0.3x 0.5x
PDEX Unlock Forecast - 30 Days FREE Trial $115M 12.9x 3.2x
PEN Unlock Forecast - 30 Days FREE Trial $10023M 67.9x 7.8x
PLRZ Unlock Forecast - 30 Days FREE Trial $7M x 0.4x
PMI Unlock Forecast - 30 Days FREE Trial $44M x x
PODD Unlock Forecast - 30 Days FREE Trial $23673M 100.3x 16.2x
PRCT Unlock Forecast - 30 Days FREE Trial $2075M -45.4x 5.4x
PROF Unlock Forecast - 30 Days FREE Trial $130M x 3.3x
PYPD Unlock Forecast - 30 Days FREE Trial $54M x 2.6x
RCEL Unlock Forecast - 30 Days FREE Trial $145M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $42M x 15.8x
RMD Unlock Forecast - 30 Days FREE Trial $40361M 28.8x 6.8x
RSMDF Unlock Forecast - 30 Days FREE Trial $3663M 2.6x 0.6x
RTGN Unlock Forecast - 30 Days FREE Trial $66M x x
RVP Unlock Forecast - 30 Days FREE Trial $25M -0.9x 0.3x
SGHT Unlock Forecast - 30 Days FREE Trial $187M -3.7x 2.7x
SIBN Unlock Forecast - 30 Days FREE Trial $628M -14.3x 3.7x
SKIN Unlock Forecast - 30 Days FREE Trial $321M -1.8x 4.3x
SNOA Unlock Forecast - 30 Days FREE Trial $7M -5.6x 1.7x
SNWV Unlock Forecast - 30 Days FREE Trial $299M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $13015M 34.3x 3.6x
SRTS Unlock Forecast - 30 Days FREE Trial $51M 31.6x 1.0x
SSKN Unlock Forecast - 30 Days FREE Trial $7M -8.0x 21.3x
STIM Unlock Forecast - 30 Days FREE Trial $213M -1.0x 7.9x
STME Unlock Forecast - 30 Days FREE Trial $12M x x
STSS Unlock Forecast - 30 Days FREE Trial $8M -2.5x 0.6x
SYK Unlock Forecast - 30 Days FREE Trial $140684M 42.0x 12.0x
TCMD Unlock Forecast - 30 Days FREE Trial $333M 22.0x 1.7x
TELA Unlock Forecast - 30 Days FREE Trial $73M -1.8x 8.0x
TFX Unlock Forecast - 30 Days FREE Trial $5676M 29.6x 1.3x
TNDM Unlock Forecast - 30 Days FREE Trial $849M -17.1x 6.4x
TNON Unlock Forecast - 30 Days FREE Trial $10M -0.3x 1.4x
USAQ Unlock Forecast - 30 Days FREE Trial $2M x x
UTMD Unlock Forecast - 30 Days FREE Trial $204M 16.2x 1.7x
VERO Unlock Forecast - 30 Days FREE Trial $5M 0.0x 2.2x
WST Unlock Forecast - 30 Days FREE Trial $18362M 37.7x 6.3x
XTNT Unlock Forecast - 30 Days FREE Trial $96M -478.8x 2.0x

Frequently Asked Questions - Sonoma Pharmaceuticals, Inc. Stock Forecast

How accurate are Sonoma Pharmaceuticals, Inc. stock predictions?

Our AI model demonstrates 51% historical accuracy for SNOA predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence Sonoma Pharmaceuticals, Inc. stock price forecasts?

Our analysis considers Sonoma Pharmaceuticals, Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Sonoma Pharmaceuticals, Inc. a good investment in 2025?

Based on our AI analysis, Sonoma Pharmaceuticals, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Sonoma Pharmaceuticals, Inc. forecasts updated?

Sonoma Pharmaceuticals, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Sonoma Pharmaceuticals, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Sonoma Pharmaceuticals, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...